Gossamer Bio, INC 8-K filings

Gossamer Bio announced the reacquisition of worldwide rights to seralutinib from Chiesi, alongside a planned September 2026 NDA submission for PAH following FDA feedback.

Gossamer Bio announced the conversion rate for its 2030 Convertible Notes and the exercise price for its Purchase Warrants, with a reference price of $0.17.

Gossamer Bio announced final results for its exchange offer, successfully exchanging a significant portion of its 5.00% Convertible Senior Notes due 2027 for new 7.50% Convertible Senior Secured First Lien Notes due 2030, common stock, and warrants.

Gossamer Bio announced an extension of the early tender deadline for its exchange offer and consent solicitation for its 5.00% Convertible Senior Notes due 2027.

Gossamer Bio initiates an exchange offer for its 5.00% Convertible Senior Notes due 2027, proposing new notes, common stock, and warrants, alongside a consent solicitation to amend indenture covenants.

Gossamer Bio received a notice from Nasdaq indicating its common stock has fallen below the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Select Market.

Gossamer Bio announced its fourth quarter and full-year 2025 financial results, alongside topline Phase 3 PROSERA study results for seralutinib which narrowly missed its primary endpoint.

Gossamer Bio announced topline results from its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension, which did not meet its primary endpoint but showed compelling signals in high-risk subgroups.

Gossamer Bio announced its third quarter 2025 financial results, highlighted by $180.2 million in cash and an expected February 2026 readout for the PROSERA Phase 3 study.

Gossamer Bio, Inc. has entered into an agreement granting it the option to acquire Respira Therapeutics, Inc., involving significant equity issuance.

Gossamer Bio reports a net loss of $38.3 million in Q2 2025, driven by a one-time revenue decrease, while advancing its seralutinib clinical programs with key milestones expected in 2025 and 2026.

Gossamer Bio, Inc. announced that its stockholders approved the Amended and Restated 2019 Incentive Award Plan and re-elected three Class I directors at its annual meeting held on June 25, 2025.

Gossamer Bio, Inc. announced the successful completion of enrollment for its global registrational Phase 3 PROSERA Study evaluating seralutinib for pulmonary arterial hypertension (PAH), with topline results anticipated in February 2026.

Gossamer Bio reports progress on its Phase 3 PROSERA study for PAH, anticipates enrollment completion in early June, and announces Q1 2025 financial results.

Gossamer Bio reports its Q4 and full-year 2024 financial results, highlighting progress with Seralutinib and a strong cash position.

Gossamer Bio, Inc. has received notification from Nasdaq that it has regained compliance with the minimum bid price requirement for continued listing.

Gossamer Bio announced its third quarter 2024 financial results, highlighting $327 million in cash, cash equivalents, and marketable securities, and provided an update on its clinical programs.

Gossamer Bio has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement for continued listing.

Gossamer Bio announced strong second quarter 2024 financial results, highlighted by a significant collaboration with Chiesi Group and progress in their Phase 3 clinical trial for seralutinib.

Gossamer Bio has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.

Gossamer Bio held its annual meeting, re-electing two directors, ratifying its auditor, and approving executive compensation on an advisory basis.

Gossamer Bio has been notified by Nasdaq that its stock price has fallen below the minimum bid price requirement for continued listing.

Gossamer Bio reported its first quarter 2024 financial results, highlighted by a new co-commercialization deal with Chiesi and progress in its seralutinib clinical trials.

Gossamer Bio and Chiesi Group have entered a global collaboration to develop and commercialize seralutinib for pulmonary hypertension, including a $160 million upfront payment to Gossamer.

Gossamer Bio has appointed Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors, signaling a strategic expansion into pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Gossamer Bio announced its fourth quarter and full-year 2023 financial results, highlighted by the first patient dosed in the Phase 3 PROSERA study for pulmonary arterial hypertension (PAH) and the inclusion of Japanese sites in the trial.

Gossamer Bio has successfully regained compliance with Nasdaq's minimum bid price requirement, resolving a previous non-compliance issue.